Alternative donor BMT with post-transplant cyclophosphamide as initial therapy for acquired severe aplastic anemia
Amy E. DeZern(Johns Hopkins University), Robert A. Brodsky(Johns Hopkins University), Philip Imus(Sidney Kimmel Cancer Center), Nina D. Wagner‐Johnston(Sidney Kimmel Comprehensive Cancer Center), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Kenneth R. Cooke(Johns Hopkins University), Tania Jain(Johns Hopkins University), Leo Luznik(Johns Hopkins University), Marianna Zahurak(Bloomberg (United States)), Ephraim J. Fuchs(Johns Hopkins University), Richard F. Ambinder(Johns Hopkins University), Carol Ann Huff(Sidney Kimmel Comprehensive Cancer Center), Mark J. Levis(Sidney Kimmel Cancer Center), Javier Bolaños‐Meade(Johns Hopkins University), Lode J. Swinnen(Johns Hopkins University), Heather J. Symons(Johns Hopkins University)
Cited by 41
Related Papers
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k